In reaction to strong earnings/guidance:
- BCOV +17.6%, NTGR +10.8%, PLXS +10.5%, MTH +9.8%, AN +8.7%, HZO +8.1%, UFPI +7.7%, UN +7.5%, EFX +5.4%, TWTR +5.4%, HNI +5.1%, CLB +4.7%, ECHO +4.4%, WST +4.4%, GTLS +4.2%, PHM +4%, ENTG +3.8%, POOL +3.7%, WHR +3.4%, STM +3.1%, GL +3%, TSLA +2.9%, DHR +2.8%, TSCO +2.8%, PNR +2.8%, PTEN +2.7%, KMB +2.4%, HBAN +2.3%, HRI +2.2%, HSY +2.2%, CLGX +2.2%, VMI +2.1%, TRV +1.8%, CTXS +1.7%, UMPQ +1.5%, T +1.2%, SAVE +1.1% (also announces stock offering), WSO +1.1%, AAL +1%, FCX +1%
Other news:
- BXG +16.3% (declares special dividend)
- AMAG +11.7% (enters into exclusive licensing agreement for ciraparantag in Europe, Australia, and New Zealand with Norgine B.V.) KLDO +7.7% (initiates a controlled clinical study (K032) being conducted with Massachusetts General Hospital, evaluating KB109 added to Supportive Self-Care for outpatients with mild-to-moderate COVID-19)
- YCBD +6% (extending its Official CBD marketing partnership with Bellator MMA)
- BCLI +5.9% (completes first milestone in developing exosome-based platform technology for the treatment of severe COVID-19 infection)
- OMC +3.2% (in sympathy with advertising peer Publicis - reported better than expected results in EU)
- WPP +1.6% (in sympathy with advertising peer Publicis - reported better than expected results in EU)
- BRKL +1.2% (files for $200 mln mixed securities shelf offering)
- BNTX +1.2% (upsizes offering by 500k shares and prices 5.5 mln ADSs at $93.00 per ADS)
- INCY +1% (announces that Phase 3 REACH3 ruxolitinib trial met primary and key secondary endpoints)
Analyst comments:
- GNFT +4.2% (upgraded to Buy from Hold at Stifel)
- BLMN +2.5% (upgraded to Neutral from Underperform at BofA Securities)
- SRDX +2% (upgraded to Buy from Hold at Needham)
- APA +1.9% (upgraded to Overweight from Neutral at JP Morgan)
- MRO +1% (upgraded to Overweight from Neutral at JP Morgan)
- TXN +1% (upgraded to Buy from Hold at DZ Bank)